Relugolix - As per NICE TA995 | Search results | NICE

Showing 1 result for relugolix - as per nice ta995

Sort by

Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Result type
Technology appraisal guidance
Published
14 August 2024
View recommendations for TA995
Show all sections
Sections for TA995